Banque Transatlantique SA Purchases Shares of 15,468 TG Therapeutics, Inc. $TGTX

Key Points

• Banque Transatlantique SA has invested approximately $610,000 in TG Therapeutics, acquiring 15,468 shares during the first quarter.
• Analysts have set a new price target of $37.00 for TG Therapeutics, with an average rating of "Moderate Buy" and an average price target of $46.25.
• TG Therapeutics reported a 92.1% increase in quarterly revenue year-over-year, reaching $141.15 million, although it missed the EPS consensus estimate.

Banque Transatlantique SA purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 15,468 shares of the biopharmaceutical company's stock, valued at approximately $610,000.

A number of other large investors have also made changes to their positions in TGTX. Allspring Global Investments Holdings LLC increased its holdings in TG Therapeutics by 54.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company's stock worth $898,000 after purchasing an additional 8,338 shares in the last quarter. New York State Teachers Retirement System lifted its stake in TG Therapeutics by 175.0% in the 1st quarter. New York State Teachers Retirement System now owns 120,364 shares of the biopharmaceutical company's stock valued at $4,746,000 after purchasing an additional 76,600 shares during the last quarter. Crossmark Global Holdings Inc. acquired a new stake in TG Therapeutics in the 1st quarter valued at about $226,000. GAMMA Investing LLC lifted its stake in TG Therapeutics by 77.7% in the 1st quarter. GAMMA Investing LLC now owns 4,543 shares of the biopharmaceutical company's stock valued at $179,000 after purchasing an additional 1,986 shares during the last quarter. Finally, Braun Stacey Associates Inc. lifted its position in TG Therapeutics by 13.5% during the first quarter. Braun Stacey Associates Inc. now owns 502,650 shares of the biopharmaceutical company's stock worth $19,819,000 after acquiring an additional 59,845 shares during the last quarter. Institutional investors own 58.58% of the company's stock.

Insider Transactions at TG Therapeutics

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the completion of the sale, the director directly owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. The trade was a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 10.64% of the stock is currently owned by insiders.

TG Therapeutics Trading Up 1.0%

Shares of NASDAQ:TGTX traded up $0.32 during mid-day trading on Friday, reaching $32.21. 2,234,151 shares of the company's stock were exchanged, compared to its average volume of 2,260,618. The firm has a market capitalization of $5.11 billion, a price-to-earnings ratio of 87.05 and a beta of 1.88. The business's fifty day moving average price is $32.81 and its 200-day moving average price is $35.59. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.96 and a current ratio of 3.86. TG Therapeutics, Inc. has a twelve month low of $21.11 and a twelve month high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing analysts' consensus estimates of $0.32 by ($0.15). The business had revenue of $141.15 million for the quarter, compared to analyst estimates of $147.76 million. TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.TG Therapeutics's revenue for the quarter was up 92.1% on a year-over-year basis. During the same quarter last year, the firm posted $0.04 EPS. TG Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group upgraded shares of TG Therapeutics to a "hold" rating and set a $37.00 price objective for the company in a research report on Thursday, July 10th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $46.25.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.